美股
Lead report
Axogen Targets 24% Revenue Growth to $279M by 2026: Breast Reconstruction Nerve Repair Accelerates, Driving MedTech Stock
Axogen issued a strong 2026 revenue guidance of at least $279 million, representing 24% growth, driven by accelerating adoption of its nerve repair products in breast reconstruction surgery. The company's strategic focus and market positioning are analyzed, along with investment risks.
